Home Services Training and Events Scientific Impact Contact

Scientific Impact

Diagnostic Development's scientific contributions and impacts.

Recent publications

  • “The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative” Cancer Cell 2025 Apr 14;43(4):587-592 https://pubmed.ncbi.nlm.nih.gov/40185094/
  • “Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion” Cancer Discov. 2025 Apr 2;15(4):793-817 https://pubmed.ncbi.nlm.nih.gov/39776167/
  • “Development of the Ontario Hereditary Cancer Research Network, a unified registry as a resource for individuals with inherited cancer syndromes: an observational registry creation protocol” BMJ Open. 2024 Nov 24;14(11) https://pubmed.ncbi.nlm.nih.gov/39581712/
  • “A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer” Hernando-Calvo A et al. Clin Colorectal Cancer. 2024 https://pubmed.ncbi.nlm.nih.gov/38960798/
  • “Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.” Chapman JW et al. J Clin Oncol. 2024 https://pubmed.ncbi.nlm.nih.gov/38824432/
  • “Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial” Bartlett JMS et al. Clin Cancer Res. 2024 https://pubmed.ncbi.nlm.nih.gov/38345755/
  • “Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance” Berman DM et al. J Urol. 2023 https://pubmed.ncbi.nlm.nih.gov/37126232/
  • “Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study” Acs B et al. Mod Pathol. 2022 https://pubmed.ncbi.nlm.nih.gov/35729220/
  • “Evaluation of multiple transcriptomic gene risk signatures in male breast cancer” Bayani J, Poncet C et al. NPJ Breast Cancer 2021 https://pubmed.ncbi.nlm.nih.gov/34312396/
  • “Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study” Bartlett JMS, Bayani J, Kornega E et al. NPJ Breast Cancer 2021 https://pubmed.ncbi.nlm.nih.gov/34238931/
  • “Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer” Chong T et al. J Ovarian Res 2018 https://pubmed.ncbi.nlm.nih.gov/29618387/